Advocacy intelligence hub — real-time data for patient organizations
IXIARO: FDA approved
IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
IXIARO
Intercell AG
IXIARO
(Japanese encephalitis vaccine, inactivated, adsorbed)Orphan drugIntercell AG
Olli Vapalahti, MD PhD
Haartman Institute, University of Helsinki
Eili Huhtamo, PhD
Haartman Institute, University of Helsinki
Anu Kantele, MD PhD
Helsinki University Central Hospital
Astrid Kaltenboeck, Ph.D.
Valneva Austria GmbH
Lars Rombo, MD PhD
Karolinska Institutet
Kulkanya Chokephaibulkit, Professor
Siriraj Hospital